The concomitant use of angiotensin Ⅱ receptor blocker (ARB) with low doses of hydrochlorothiazide (HCTZ) may provide additional antihypertensive activity. HCTZ induces hypokalemia and hyperglycemia, while ARB slightly induces hyperkalemia. Recently, it has been reported that ARB/ HCTZ did not worsen fasting blood sugar levels; however, the detailed glucose tolerance change effect with combination therapy of ARB/HCTZ compared to ARB alone therapy remains to be investigated. 
Introduction
Hypertension is one of the most crucial risk factors for the occurrence of both cardiovascular and cerebrovascular events [1] [2] [3] [4] . It has been indicated that attaining a target blood pressure should be the primary goal for patients with hypertension according to the Japanese Society of Hypertension, the American Society of Hypertension and the European Society of Hypertension 5, 6) . It is very difficult for most hypertension patients to control their blood pressure with only one antihypertensive medicine, and frequently two or three antihypertensive medicines are used simultaneously 5) . The angiotensin Ⅱ receptor blocker (ARB) is currently one of the most frequently used first-choice antihypertensive medicines. ARBs have few side effects and provide organ protection, including the improvement of renal function, vascular endothelium function, platelet aggregability and atherosclerosis [7] [8] [9] [10] [11] . Hydrochlorothiazide (HCTZ), another antihypertensive medication, reduces sodium reabsorption in the distal convoluted tubules. The major site of were switched to 50 mg Losartan with 12.5 mg HCTZ combinations. The 75 g oral glucose tolerance test (75 g OGTT) was performed before and after switching, at 3 months. Blood glucose and insulin levels before, and 30, 60 and 120 minutes after 75 g glucose intake on the 75 g OGTT, homeostasis model assessment as an index of insulin resistance {HOMA-IR: fasting glucose (mg/dL)×fasting insulin (μU/mL)/ 405}, and the whole body insulin sensitivity index {WBISI: 10,000/square root of (fasting glucose×fast-ing insulin)×(mean glucose×mean insulin during 75 g OGTT)} were compared before and after switching medications 10, 16, 17) .
Statistical Analysis and Ethical Issues
Continuous data for the 30 patients are expressed as the mean±SD or median.
Differences between data were examined utilizing Spearman's rank correlation coefficient for paired data. Categorical values are presented as numbers. A probability value ＜0.05 was considered to indicate statistical significance.
The statistics software was the Statistical Package for Social Sciences, version 19 (SPSS Inc., Chicago, IL). The study protocol was approved by the Human Ethics Review Committee of Kumamoto University and a signed consent form was obtained from each subject.
Results
Between May 2008 and May 2010, 30 non-DM hypertensive patients with a mean age of 66.5 years and a mean BMI of 25.3 kg/m 2 were studied. Table 1 summarizes the characteristics of the patients at baseline.
As is shown in Table 2 , non-DM hypertensive patients took common doses of ARBs (5 patients (pts): Losartan 50 mg; 8 pts: Valsartan 80 mg; 9 pts: Candesartan 8 mg; 4 pts: Termisartan 40 mg; and, 4 pts: Olmesartan 20 mg) before switching to 50 mg Losartan with 12.5 mg HCTZ. They also took antihypertensive medicines ( Table 2 ). The regimens of these medicines, except for the ARBs, did not change before or after this study. Table 3 shows vital and blood data of the patients before and after switching the medication regimens. Systolic blood pressure improved from 146.6±17.0 to 131.4±10.0 mmHg and diastolic blood pressure improved from 83.4±10.4 to 73.8±8.8 mmHg. Heart rates before and after switching regimens were not significantly changed (68.4±8.7 to 68.0±11.1 beats per minutes). Serum creatinine, uric acid and electrolyte action, in the nephron, appears to be on an electroneutral Na ＋ -Cl − co-transporter. By impairing Na transport in the distal convoluted tubules, HCTZ induces natriuresis and concomitant water loss. Low doses of HCTZ are very effective sodium eccritics, and low doses of HCTZ are very useful as antihypertensive medications; however, HCTZ induces hypokalemia and, as a result, it worsens glucose tolerance 12) . The concomitant use of low doses of HCTZ with losartan may induce additive antihypertensive effects. Although HCTZ induces hypokalemia and hyperglycemia and causes renal damage, ARBs tend to offset these effects. Recently, it has been reported that ARB combined with HCTZ did not worsen hemoglobin A1C or fasting blood sugar levels.
The prescription of thiazide, a diuretic, has certain limits, specifically that it does not increase adverse effects [13] [14] [15] ; however, there are concerns about the glucose tolerance effects of thiazide.
The detailed effects of a fixed combination of 50 mg Losartan with 12.5 mg HCTZ on glucose tolerance and renal function remain to be elucidated in Japanese hypertensive patients uncontrolled with common doses of ARBs.
Methods

Study Population and Design
This study was designed as a self-control study between May 2008 and May 2010 at ten cardiovascular centers in Kumamoto and Tamana cities, Japan (Kumamoto University Hospital, et al.). The subjects of this study comprised 30 consecutive out-clinic, non-diabetic patients (20-80 years old, 10 male and 20 female) who had uncontrolled hypertension with common doses of ARBs (Losartan: 50 mg; Candesartan: 8 mg; Olmesartan: 20 mg; Valsartan: 80 mg), or common doses of ARBs and antihypertensive medicines, without diuretics for more than one month. Uncontrolled hypertension was defined as clinical systolic BP ＞140 mmHg at any time and/or clinical diastolic BP ＞90 mmHg at any time 5) . Exclusion criteria were the following: diabetes mellitus; secondary hypertension; heart failure (New York Heart Association Ⅲ and Ⅳ); patients receiving diuretics; pregnant or possibly pregnant women; liver dysfunction; renal dysfunction; patients with hypersensitivity for either losartan or HCTZ.
After written informed consent was obtained from each patient, treated non-diabetes mellitus (DM) hypertensive patients taking common doses of ARBs, who were not achieving their blood pressure goals, ameliorated: 1.59±1.1 to 1.52±0.9; 5.5±3.2 to 5.6 ±3.4, respectively, see Fig. 1 . The decrease in systolic blood pressure was significantly correlated with the decrease in HOMA-IR after switching drugs (R = 0.508, p = 0.010); however, the decrease in diastolic blood pressure was not correlated with the HOMA-IR change. WBISI was not related in any significant way with either systolic or diastolic blood pressure.
Fourteen patients had IGT with hypertension and 16 patients did not. In both IGT and non-IGT patients, glucose and insulin levels did not significantly change. HOMA-IR after the drug change in IGT patients was significantly lower than before the drug change (2.1±1.4 to 1.8±0.9: p=0.024). HOMA-IR in non-IGT patients did not significantly change (1.1±0.5 to 1.3±0.9: n.s.). As regards insulin sensitivity between IGT and non-IGT patients, WBISI was not significantly changed before or after the drug change (IGT patients: 4.81±2.8 to 4.8±2.2; non-IGT patients: 6.7±3.9 to 6.3±3.6: n.s.).
Discussion
It has been previously reported that there was no change in hemoglobin A1C or in fasting blood glucose levels when changing from common doses of ARBs to ARB combined with HCTZ [18] [19] [20] . There was a concern that glucose tolerance would be worsened when switching from common doses of ARBs to 50 mg Losartan with 12.5 mg HCTZ for hypertension patients, but in this study, we report for the first time that glucose tolerance was not worsened, even if these medicines regimens were changed, using the 75 g OGTT. We also report herein that insulin resistance levels were unchanged. The urine albumin/creatinine ratio was significantly improved (28.9±99.4 to 22.0± 20.4 (mg/g · Cre), p = 0.009) Table 4 shows serum glucose levels and immunoreactive insulin levels (fasting, 30, 60, 120 min) on the 75 g OGTT before switching and at 3 months after switching to 50 mg Losartan with 12.5 mg HCTZ from ARBs. After switching, blood glucose levels at fasting, 30, 60 and 120 minutes, on the 75 g OGTT, were significantly decreased: 105.3±15.7 to 102.3±14.2; 180.5±31.4 to117.7±33.4; 188.5± 52.4 to 170.6±53.5; 153.0±44.3 to 151.3±52.4 (mg/dL), respectively. Blood insulin levels at 30 and 120 minutes on the 75 g OGTT were significantly decreased: 55.5±36.4 to 52.9±39.6; 55.5±37.6 to 51.4±29.4 (μIU/mL), respectively. Blood insulin levels at fasting and at 60 minutes on the 75 g OGTT did not change significantly.
The insulin resistance index, HOMA-IR, and the insulin sensitivity index, WBISI, were significantly insulin levels and HOMA-IR were all ameliorated with 75 g OGTT within three months 22) . In our study, the glucose tolerance level was slightly but significantly improved by changing from ARBs to ARB/ HCTZ. We need to emphasize that glucose tolerance was not worsened in this study because of the medications per se. The maintenance of similar levels of potassium could be one of the major contributors to avoiding glucose metabolism disturbance. Systolic blood pressure decreases ameliorated HOMA-IR in our study; therefore, improvement of insulin resistance might ameliorate glucose tolerance 12, [23] [24] [25] . It was reported that glucose levels at 120 minutes, HbA1c, and insulin levels were significantly increased with Losartan/HCTZ (doses increased from Losartan 50 and insulin sensitivity, such as measured utilizing HOMA-IR or WBISI, were both significantly improved in this study.
By changing from ARBs to 50 mg Losartan with 12.5 mg HCTZ, we were able to adequately control both systolic blood pressure and diastolic blood pressure, bringing them both to within normal ranges. There were no significant changes in heart rate or liver function, renal function, uric acid level or serum electrolyte level. It has been reported that home blood pressure is a better predictor of prognosis than blood pressure obtained in a doctor's office; however, we did not check home blood pressure either before or after the drug changes 21) . It has previously been reported that glucose, Values are the mean±SD exercise effects. Further studies should be considered to perform body weight, BMI and abdominal circumference measurements three months after the medicine regimen change. Total cholesterol and high density lipoprotein cholesterol levels did not significantly change, and triglycerides levels increased and LDL cholesterol levels decreased; therefore, few, if any, effects of diet and/or exercise therapy were evident as regards key metabolic syndrome factors.
It has been reported that low doses of HCTZ caused hypokalemia and glucose tolerance aggravation within three months, but we showed that ARB constrained the effect of HCTZ when we changed from a common dose of ARBs to ARB with HCTZ 27, 28) . The significant improvement of the urine albumin/creatinine ratio might be due to the effect of adequate lowering of blood pressure 29) . We examined the correlations between the albumin/creatinine ratio with renal function, changes in blood pressure and the value of the uric acid level, but no significant findings were obtained in any case.
Conclusion
On the 75 g OGTT, using 50 mg Losartan and 12.5 mg HCTZ combination, switched from commg/HCTZ 12.5 mg to Losartan 100 mg/HCTZ 25 mg) in the STAR study, and this effect seems to be related to thiazide-induced hypokalemia, which is clearly dependent on the HCTZ dose 12, 26) . In IGT patients and non-IGT patients with hypertension, glucose and insulin levels and WBISI did not significantly change, although insulin resistance was ameliorated in the IGT group. In 4 cases, glucose tolerance worsened. Glucose tolerance, HOMA-IR and WBISI were not significantly worsened, but they did demonstrate a tendency to worsen. Their electrolyte levels and renal functions were unchanged. Deterioration of glucose tolerance was observed in cases of worsening insulin resistance and insulin sensitivity.
We examined the differences between each ARB, such as Losartan, Olmesartan et al., to determine their effects on blood pressure and glucose tolerance, but no significant findings were obtained. A low dose of HCTZ did not worsen uric acid levels because of the contrary effects of Losartan.
We performed this study over three months, so there were probably few effects of diet or exercise therapies, so we did not check body weight and body mass index (BMI) after the drug change; therefore, we are not able to completely reject the existence of diet and 
HOMA-IR WBISI
Before Switching After Switching Before Switching After Switching P89:9991 P89:9993 mon doses of ARBs, did not worsen glucose tolerance but did improve blood pressure, HOMA-IR and WBISI levels in hypertensive non-DM Japanese patients.
